Sound Income Strategies LLC Lowers Holdings in GSK PLC Sponsored ADR $GSK

Sound Income Strategies LLC cut its position in GSK PLC Sponsored ADR (NYSE:GSK) by 3.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 396,020 shares of the pharmaceutical company’s stock after selling 16,037 shares during the period. Sound Income Strategies LLC’s holdings in GSK were worth $19,096,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Florida Trust Wealth Management Co raised its holdings in GSK by 3.8% in the fourth quarter. Florida Trust Wealth Management Co now owns 12,466 shares of the pharmaceutical company’s stock worth $611,000 after buying an additional 461 shares during the last quarter. Trust Co. of Toledo NA OH raised its holdings in GSK by 3.7% in the fourth quarter. Trust Co. of Toledo NA OH now owns 32,617 shares of the pharmaceutical company’s stock worth $1,600,000 after buying an additional 1,162 shares during the last quarter. Bank & Trust Co raised its holdings in GSK by 657.7% in the fourth quarter. Bank & Trust Co now owns 2,061 shares of the pharmaceutical company’s stock worth $101,000 after buying an additional 1,789 shares during the last quarter. First Bank & Trust raised its stake in shares of GSK by 10.1% in the fourth quarter. First Bank & Trust now owns 56,333 shares of the pharmaceutical company’s stock worth $2,763,000 after purchasing an additional 5,182 shares during the last quarter. Finally, Peoples Bank KS raised its stake in shares of GSK by 6.3% in the fourth quarter. Peoples Bank KS now owns 5,030 shares of the pharmaceutical company’s stock worth $247,000 after purchasing an additional 300 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GSK has been the subject of several recent analyst reports. Weiss Ratings cut GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 19th. HSBC restated a “reduce” rating on shares of GSK in a research note on Wednesday, December 10th. TD Cowen restated a “hold” rating on shares of GSK in a research note on Monday, February 9th. Barclays restated an “underweight” rating on shares of GSK in a research note on Friday, February 20th. Finally, Wall Street Zen cut GSK from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 7th. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, GSK currently has a consensus rating of “Reduce” and a consensus price target of $44.13.

GSK Stock Down 0.5%

GSK stock opened at $56.39 on Tuesday. The stock has a market cap of $114.56 billion, a PE ratio of 15.24, a price-to-earnings-growth ratio of 3.43 and a beta of 0.46. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.54 and a current ratio of 0.82. GSK PLC Sponsored ADR has a one year low of $32.38 and a one year high of $61.69. The stock has a fifty day moving average of $55.95 and a 200 day moving average of $49.97.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 9th. Shareholders of record on Friday, February 20th will be given a $0.4856 dividend. The ex-dividend date is Friday, February 20th. This is a positive change from GSK’s previous quarterly dividend of $0.42. This represents a $1.94 dividend on an annualized basis and a yield of 3.4%. GSK’s dividend payout ratio (DPR) is currently 51.62%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.